December 14, 2023.

Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.

More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.